WJCD  Vol.3 No.2 A , April 2013
The use of diuretics in acute heart failure: Evidence based therapy?

The evidence base for the use of diuretics in acute heart failure is limited, with no large double-blind placebo-controlled randomized trials. However, their use as a first line treatment of acute heart failure is firmly established in clinical practice, and endorsed in clinical guidelines. Loop diuretics are typically the first line diuretic strategy for the treatment of acute heart failure. For patients with considerable fluid retention, there is some evidence that initial treatment with continuous infusion or boluses of high dose loop diuretic is superior to an initial lower dose strategy. In patients who are diuretic resistant, the addition of an oral thiazide or thiazide-like diuretic to induce sequential nephron blockade can be beneficial. Intravenous low-dose dopamine has also been used to assist diuresis and preserve renal function in such circumstances, but trials are underway to confirm the clinical value of this agent. Mechanical ultrafiltration has been used to treat patients with heart failure and fluid retention, but the evidence base is not secure, and its place in clinical practice is yet to be established.

Cite this paper
Vazir, A. and Cowie, M. (2013) The use of diuretics in acute heart failure: Evidence based therapy?. World Journal of Cardiovascular Diseases, 3, 25-34. doi: 10.4236/wjcd.2013.32A004.
[1]   Southey, R. (1877) Chronic parenchymatous nephritis of right kidney, left kidney small, atrophied. Old scrofulous pyelitis. Transactions of the Clinical Society of London, 10, 152-156.

[2]   Krishnakumar, N., Harikrishnan, S. and Tharakan, J.M. (2007) Self-blood letting in congestive cardiac failure. International Journal of Cardiology, 114, 135-136.

[3]   Withering, W. (1785) An account of the foxglove and some of its medical uses: With practical remarks on dropsy and other diseases. J & J Robinson, Yellowknife. doi:10.5962/bhl.title.3869

[4]   Vogl, A. (1950) The discovery of the organic mercurial diuretics. American Heart Journal, 39, 881-883.

[5]   Novello, F.C. (1957) Benzothiadiazine dioxides as novel duiretics. Journal of the American Chemical Society, 79, 2028. doi:10.1021/ja01565a079

[6]   Robson, A.O., Kerr, D.N., Ashcroft, R. and Teasdale, G. (1964) The diuretic response to frusemide. Lancet, 2, 1085-1088.

[7]   Jessup, M., Abraham, W.T., Casey, D.E., Feldman, A.M., Francis, G.S., Ganiats, T.G., et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation, 119, 1977-2016.

[8]   McMurray, J.J., Adamopoulos, S., Anker, S.D., Auricchio, A., Bohm, M., Dickstein, K., et al. (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Journal of Heart Failure, 14, 803869.

[9]   Maxwell, A.P., Ong, H.Y. and Nicholls, D.P. (2002) Influence of progressive renal dysfunction in chronic heart failure. European Journal of Heart Failure, 4, 125-30.

[10]   Wilson, T.W., McCauley, F.A. and Wells, H.D. (1986) Effects of low-dose aspirin on responses to furosemide. Journal of Clinical Pharmacology, 26, 100-105.

[11]   Brater, D.C., Chennavasin, P. and Dehmer, G.J. (1984) Prolonged hemodynamic effect of furosemide in congestive heart failure. American Heart Journal, 108, 10311032.

[12]   Johnston, G.D., Nicholls, D.P. and Leahey, W.J. (1984) The dose-response characteristics of the acute non-diuretic peripheral vascular effects of frusemide in normal subjects. British Journal of Clinical Pharmacology, 18, 75-81.

[13]   Rybak, L.P. (1985) Furosemide ototoxicity: Clinical and experimental aspects. The Laryngoscope, 95, 1-14.

[14]   Vermeulen, A. and Chadha, D.R. (1982) Slow-release furosemide and hydrochlorothiazide in congestive cardiac failure: A controlled trial. Journal of Clinical Pharmacology, 22, 513-519.

[15]   Dargie, H.J., Allison, M.E., Kennedy, A.C. and Gray, M.J. (1972) High dosage metolazone in chronic renal failure. British Medical Journal, 4, 196-198.

[16]   Townsend, H.A., Waddy, A.L., Eason, C.T. and Richards, H.H. (1984) Frusemide/amiloride combination (Frumil) in heart failure: An open, multi-centre study in general practice. Current Medical Research and Opinion, 9, 132140.

[17]   Ghosh, A.K., Mankikar, G., Strouthidis, T., Windsor, A., Long, C. and Glover, D.R. (1987) A single-blind, comparative study of hydrochlorothiazide/amiloride (Moduret 25) and hydrochlorothiazide/triamterene (dyazide) in elderly patients with congestive heart failure. Current Medical Research and Opinion, 10, 573-579.

[18]   Kohvakka, A. (1988) Maintenance of potassium balance during long-term diuretic therapy in chronic heart failure patients with thiazide-induced hypokalemia: Comparison of potassium supplementation with potassium chloride and potassium-sparing agents, amiloride and triamterene. International Journal of Clinical Pharmacology, Therapy, and Toxicology, 26, 273-277.

[19]   Krishna, G.G., Shulman, M.D. and Narins, R.G. (1988) Clinical use of the potassium-sparing diuretics. Seminars in Nephrology, 8, 354-364.

[20]   Kourouklis, C., Christensen, O. and Augoustakis, D. (1976) Bumetanide in congestive heart failure. Current Medical Research and Opinion, 4, 422-431.

[21]   Haerer, W., Bauer, U., Sultan, N., Cernoch, K., Mouselimis, N., Fehske, K.J., et al. (1990) Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure—A placebo-controlled trial. Cardiovascular Drugs and Therapy/Sponsored by the International Society of Cardiovascular Pharmacotherapy, 4, 515-521.

[22]   Kleber, F.X. and Thyroff-Friesinger, U. (1990) Treatment of mild chronic congestive heart failure with ibopamine, hydrochlorothiazide, ibopamine plus hydrochlorothiazide or placebo. A double-blind comparative study. Cardiology, 77, 67-74.

[23]   Patterson, J.H., Adams Jr., K.F., Applefeld, M.M., Corder, C.N. and Masse, B.R. (1994) Oral torsemide in patients with chronic congestive heart failure: Effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy, 14, 514-521.

[24]   Sherman, L.G., Liang, C.S., Baumgardner, S., Charuzi, Y., Chardo, F. and Kim, C.S. (1986) Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clinical Pharmacology and Therapeutics, 40, 587-594.

[25]   Stewart, J.H. and Edwards, K.D. (1965) Clinical comparison of frusemide with bendrofluazide, mersalyl, and ethacrynic acid. British Medical Journal, 2, 1277-1281.

[26]   Faris, R., Flather, M., Purcell, H., Henein, M., PooleWilson, P. and Coats, A. (2002) Current evidence supporting the role of diuretics in heart failure: A meta analysis of randomised controlled trials. International Journal of Cardiology, 82, 149-158.

[27]   Crawford, R.J., Allman, S., Gibson, W., Kitchen, S. and Richards, H.H. (1988) A comparative study of frusemideamiloride and cyclopenthiazide-potassium chloride in the treatment of congestive cardiac failure in general practice. The Journal of International Medical Research, 16, 143149.

[28]   Gonska, B.D. and Kreuzer, H. (1985) Diuretic monotherapy in heart failure. Comparison of piretanide and hydrochlorothiazide-triamterene. Deutsche Medizinische Wochenschrift, 110, 1812-1816.

[29]   Gabriel, R. and Baylor, P. (1981) Comparison of the chronic effects of bendrofluazide, bumetanide and frusemide on plasma biochemical variables. Postgraduate Medical Journal, 57, 71-74.

[30]   Funke Kupper, A.J., Fintelman, H., Huige, M.C., Koolen, J.J., Liem, K.L. and Lustermans, F.A. (1986) Cross-over comparison of the fixed combination of hydrochlorothiazide and triamterene and the free combination of furosemide and triamterene in the maintenance treatment of congestive heart failure. European Journal of Clinical Pharmacology, 30, 341-343.

[31]   Noe, L.L., Vreeland, M.G., Pezzella, S.M. and Trotter, J.P. (1998) A pharmacoeconomic assessment of torsemide and furosemide in the treatment of patients with congestive heart failure. Clinical Therapeutics, 21, 854866. doi:10.1016/S0149-2918(99)80007-1

[32]   Stroupe, K.T., Forthofer, M.M., Brater, D.C. and Murray M.D. (2000) Healthcare costs of patients with heart failure treated with torasemide or furosemide. Pharmaco Economics, 17, 429-440. doi:10.2165/00019053-200017050-00002

[33]   Murray, M.D., Deer, M.M., Ferguson, J.A., Dexter, P.R., Bennett, S.J., Perkins, S.M., et al. (2001) Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. The American journal of medicine, 111, 513-520. doi:10.1016/S0002-9343(01)00903-2

[34]   Muller, K., Gamba, G., Jaquet, F. and Hess, B. (2003) Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV—Efficacy and quality of life. European journal of heart failure, 5, 793-801. doi:10.1016/S1388-9842(03)00150-8

[35]   Felker, G.M., Lee, K.L., Bull, D.A., Redfield, M.M., Stevenson, L.W., Goldsmith, S.R., et al. (2011) Diuretic strategies in patients with acute decompensated heart failure. The New England Journal of Medicine, 364, 797-805. doi:10.1056/NEJMoa1005419

[36]   Allen, L.A., Turer, A.T., Dewald, T., Stough, W.G., Cotter, G. and O’Connor, C.M. (2010) Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. The American journal of cardiology, 105, 1794-1797. doi:10.1016/j.amjcard.2010.01.355

[37]   Paterna, S., Fasullo, S., Parrinello, G., Cannizzaro, S., Basile, I., Vitrano, G., et al. (2011) Short-term effects of hypertonic saline solution in acute heart failure and long-term effects of a moderate sodium restriction in patients with compensated heart failure with New York Heart Association class III (Class C) (SMAC-HF Study). The American Journal of the Medical Sciences, 342, 2737. doi:10.1097/MAJ.0b013e31820f10ad

[38]   Tuttolomondo, A., Pinto, A., Parrinello, G. and Licata, G. (2011) Intravenous high-dose furosemide and hypertonic saline solutions for refractory heart failure and ascites. Seminars in Nephrology, 31, 513-522. doi:10.1016/j.semnephrol.2011.09.006

[39]   Neuberg, G.W., Miller, A.B., O’Connor, C.M., Belkin, R.N., Carson, P.E., Cropp, A.B., et al. (2002) Diuretic resistance predicts mortality in patients with advanced heart failure. American Heart Journal, 144, 31-38. doi:10.1067/mhj.2002.123144

[40]   Ravnan, S.L., Ravnan, M.C. and Deedwania, P.C. (2002) Pharmacotherapy in congestive heart failure: Diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail, 8, 80-85. doi:10.1111/j.1527-5299.2002.0758.x

[41]   Brater, D.C., Day, B., Burdette, A. and Anderson, S. (1984) Bumetanide and furosemide in heart failure. Kidney International, 26, 183-189. doi:10.1038/ki.1984.153

[42]   Vasko, M.R., Cartwright, D.B., Knochel, J.P., Nixon, J.V. and Brater, D.C. (1985) Furosemide absorption altered in decompensated congestive heart failure. Annals of Internal Medicine, 102, 314-318. doi:10.7326/0003-4819-102-3-314

[43]   De Silva, R., Nikitin, N.P., Witte, K.K., Rigby, A.S., Goode, K., Bhandari, S., et al. (2006) Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: Contributing factors and relationship to prognosis. European Heart Journal, 27, 569-581. doi:10.1093/eurheartj/ehi696

[44]   Stanton, B.A. and Kaissling, B. (1988) Adaptation of distal tubule and collecting duct to increased Na delivery. II. Na+ and K+ transport. The American Journal of Physiology, 255, F1269-F1275.

[45]   Kaissling, B. and Stanton, B.A. (1988) Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. The American journal of physicology, 255, F1256-F1268.

[46]   Bartoli, E., Arras, S., Faedda, R., Soggia, G., Satta, A. and Olmeo, N.A. (1980) Blunting of furosemide diuresis by aspirin in man. Journal of Clinical Pharmacology, 20, 452-458. doi:10.1002/j.1552-4604.1980.tb01718.x

[47]   Kiyingi, A., Field, M.J., Pawsey, C.C., Yiannikas, J., Lawrence, J.R. and Arter, W.J. (1990) Metolazone in treatment of severe refractory congestive cardiac failure. Lancet, 335, 29-31. doi:10.1016/0140-6736(90)90148-X

[48]   Dormans, T.P. and Gerlag, P.G. (1996) Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. European Heart Journal, 17, 1867-1874. doi:10.1093/oxfordjournals.eurheartj.a014805

[49]   Sigurd, B., Olesen, K.H. and Wennevold, A. (1975) The supra-additive natriuretic effect addition of bendroflumethiazide and bumetanide in congestive heart failure. Permutation trial tests in patients in long-term treatment with bumetanide. American Heart Journal, 89, 163-170. doi:10.1016/0002-8703(75)90041-1

[50]   Channer, K.S., McLean, K.A., Lawson-Matthew, P., Richardson, M. (1994) Combination diuretic treatment in severe heart failure: A randomised controlled trial. British Heart Journal, 71, 146-150. doi:10.1136/hrt.71.2.146

[51]   Bock, J.S. and Gottlieb, S.S. (2010) Cardiorenal syndrome: New perspectives. Circulation, 121, 2592-2600. doi:10.1161/CIRCULATIONAHA.109.886473

[52]   Elkayam, U., Ng, T.M., Hatamizadeh, P., Janmohamed, M. and Mehra, A. (2008) Renal vasodilatory action of dopamine in patients with heart failure: Magnitude of effect and site of action. Circulation, 117, 200-205. doi:10.1161/CIRCULATIONAHA.107.737106

[53]   Giamouzis, G., Butler, J., Starling, R.C., Karayannis, G., Nastas, J., Parisis, C., et al. (2010) Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the dopamine in acute decompensated heart failure (DAD-HF) trial. Journal of Cardiac Failure, 16, 922-930. doi:10.1016/j.cardfail.2010.07.246

[54]   Konstam, M.A., Gheorghiade, M., Burnett, J.C., Jr. Grinfeld, L., Maggioni, A.P., Swedberg, K., et al. (2007) Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The everest Outcome Trial. JAMA: The Journal of the American Medical Association, 297, 1319-1331. doi:10.1001/jama.297.12.1319

[55]   Gheorghiade, M., Konstam, M.A., Burnett, J.C., Jr. Grinfeld, L., Maggioni, A.P., Swedberg, K., et al. (2007) Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The everest clinical status trials. JAMA: The Journal of the American Medical Association, 297, 13321343. doi:10.1001/jama.297.12.1332

[56]   Massie, B.M., O’Connor, C.M., Metra, M., Ponikowski, P., Teerlink, J.R., Cotter, G., et al. (2010) Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. The New England Journal of Medicine, 363, 1419-1428. doi:10.1056/NEJMoa0912613

[57]   Jaski, B.E., Ha, J., Denys, B.G., Lamba, S., Trupp, R.J. and Abraham, W.T. (2003) Peripherally inserted venovenous ultrafiltration for rapid treatment of volume overloaded patients. Journal of Cardiac Failure, 9, 227231. doi:10.1054/jcaf.2003.28

[58]   Costanzo, M.R., Guglin, M.E., Saltzberg, M.T., Jessup, M.L., Bart, B.A., Teerlink, J.R., et al. (2007) Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. Journal of the American College of Cardiology, 49, 675-683. doi:10.1016/j.jacc.2006.07.073

[59]   Schroeder, K.L., Sallustio, J.E. and Ross, E.A. (2004) Continuous haematocrit monitoring during intradialytic hypotension: Precipitous decline in plasma refill rates. Nephrology, Dialysis, Transplantation: Official publication of the European Dialysis and Transplant Association-European Renal Association, 19, 652-656.

[60]   Marenzi, G., Lauri, G., Grazi, M., Assanelli, E., Campodonico, J. and Agostoni, P. (2001) Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. Journal of the American College of Cardiology, 38, 963-968. doi:10.1016/S0735-1097(01)01479-6

[61]   Marenzi, G., Grazi, S., Giraldi, F., Lauri, G., Perego, G., Guazzi, M., et al. (1993) Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: Effects of extracorporeal ultrafiltration. The American Journal of Medicine, 94, 49-56. doi:10.1016/0002-9343(93)90119-A

[62]   Ali, S.S., Olinger, C.C., Sobotka. P.A., Bernard, S., Dahle, T.G., Bunte, M.C., et al. (2006) Enhanced sodium extraction with ultrafiltration compared to intravenous diuretics. Journal of Cardiac Failure, 12, S114. doi:10.1016/j.cardfail.2006.06.393

[63]   Bart, B.A., Boyle, A., Bank, A.J., Anand, I., Olivari, M.T., Kraemer, M., et al. (2005) Ultrafiltration versus usual care for hospitalized patients with heart failure: The relief for acutely fluid-overloaded patients with decompensated congestive heart failure (RAPID-CHF) trial. Journal of the American College of Cardiology, 46, 2043-2046. doi:10.1016/j.jacc.2005.05.098

[64]   Bart, B.A., Goldsmith, S.R., Lee, K.L., Givertz, M.M., O’Connor, C.M., Bull, D.A., et al. (2012) Ultrafiltration in decompensated heart failure with cardiorenal syndrome. The New England Journal of Medicine, 367, 2296-2304. doi:10.1056/NEJMoa1210357

[65]   Kazory, A., Bellamy, F.B. and Ross, E.A. (2012) Ultrafiltration for acute decompensated heart failure: Financial implications. International Journal of Cardiology, 154, 246-249. doi:10.1016/j.ijcard.2011.05.073